Maintaining a robust stance amidst a tempest of challenges, McKesson Corporation (MCK) stands steadfast, bolstered by strategic alliances and a stalwart Distribution Solutions division. While the specter of opioid litigation looms, the company maintains its course with a Zacks Rank of #3 (Hold), showcasing a 15.4% rise in shares this year against the industry’s 6% growth. In parallel, the S&P 500 Index has surged 9.6% during this period.
In the realm of healthcare services and information technology, McKesson, with a market capitalization of $69.74 billion, eyes a promising future with a projected 11.9% earnings boost in the upcoming five years. The company boasts a track record of outperforming estimates across the last four quarters, averaging a 9.11% earnings surprise.
Image Source: Zacks Investment Research
The Ascent: Key Growth Catalysts
Investor optimism finds fertile ground in McKesson’s thriving Biologics arm, with its independent specialty pharmacy, Biologics by McKesson, marking notable strides. Partnering with Novartis for FABHALTA and SpringWorks Therapeutics for OGSIVEO, the pharmacy charts a course for growth.
Further bolstering its future, McKesson forges strategic alliances, as evidenced by extending its partnership with Genpact. This collaboration aims at enhancing automation in McKesson’s finance operations through AI solutions, promising continued efficiency.
Girded by robust fiscal Q3 results, McKesson’s U.S. Pharmaceutical segment has flourished, driven by heightened prescription volumes. This growth, fueled by specialty products, retail national accounts, and GLP-1 medications, underscores the company’s resilience.
Undercurrents: Navigating Challenges
Conversely, McKesson treads on the thin ice of generic pharmaceutical distribution, grappling with price fluctuations that sap the strength of its Distribution Solutions arm. Stiff competition further compounds the company’s challenges, as it contends with pricing negotiations amidst a supply chain landscape dotted with competitors.
Projection: Estimates Unveiled
The Zacks Consensus Estimate unveils a promising trajectory for McKesson, with fiscal 2024 revenues expected to hit $310.28 billion, marking a substantial 12.1% uptick. Adjusted earnings per share are forecasted to settle at $27.62, symbolizing a 6.5% year-over-year enhancement.
Charting the Path: Stocks to Watch
For investors seeking opportunities in the medical sphere, DaVita Inc. (DVA), Cardinal Health, Inc. (CAH), and Cencora (COR) hold promise. With DaVita boasting a Zacks Rank of #1 (Strong Buy) and remarkable growth estimates, alongside Cardinal Health and Cencora showcasing positive trends, these stocks beckon discerning investors.
Embrace the burgeoning landscape of medical stocks, synergizing astute analysis with foresight. Shifting industry winds offer opportunities for growth and prosperity — seizing the day calls forth a portal to untold potential.
Zacks Names “Single Best Pick to Double”
From thousands of stocks, 5 Zacks experts have unearthed a beacon of promise — a stock poised to surge by +100% or more. Director of Research Sheraz Mian heralds a revolutionary medical breakthrough, heralding a new dawn of hope for patients grappling with liver, lung, and blood disorders.
As the market whirls with optimism, this stock rises like a phoenix from the ashes of a bear market — an opportunity ripe for the taking. Savor the prospect of untold gains, eclipsing past marvels like Boston Beer Company and NVIDIA in the annals of stock market triumphs.
Free: See Our Top Stock And 4 Runners Up
Download 7 Best Stocks for the Next 30 Days
Original Article Source: Zacks.com
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
